ANKRD35 and cervical carcinoma: In the present study, the immune subtype-relevant signature (covering TMEM125, TFF1, DECR2, LONRF3, DAPL1, and ANKRD35) was quantified, which predicted cervical cancer recurrence accurately and independently.